Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Unmet clinical needs for platinum-resistant ovarian cancer patients

Domenica Lorusso • 29 Nov 2018
ESMO 2018
Gynecological Cancer Ovarian Cancer Doxorubicin Lurbinectedin Topotecan
CORAIL

Lurbinectedin, a novel agent, failed to exhibit superiority over standard chemotherapy treatment in the Phase III CORAIL trial (NCT02421588). Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy, discusses the implications of this result at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Domenica Lorusso

0:47
Assessing chemotherapy and immunotherapy in dMMR endometrial cancer
Domenica Lorusso • 23 Oct 2023
0:39
ESMO 2023 highlights: KEYNOTE-A18 and more
Domenica Lorusso • 23 Oct 2023
0:52
The importance of HRD testing in ovarian cancer
Domenica Lorusso • 23 Oct 2023
1:14
KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
Domenica Lorusso • 23 Oct 2023

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals